Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer

Short-Course Radiotherapy Followed by CAPOX With or Without Iparomlimab and Tuvonralimab in pMMR/MSS Locally Advanced Rectal Cancer is a phase 3, randomised interventional study registered as NCT07686640 by Shandong Cancer Hospital and Institute, with a registry enrolment figure of 180 participants, started 2026-08-15 and due to reach its primary completion in 2029-07-15. Interventions recorded: Short-Course Radiotherapy; Consolidation treatment (With ICIs); Consolidation treatment (Without ICIs). Conditions listed: Local Advanced Rectal Cancer; Radiotherapy; Immunotherapy. Primary outcome: Complete Response (CR) Rate. Colorectal eligibility wording from the registry: "* Patients aged 18-75 years with histologically confirmed pMMR/MSS rectal adenocarcinoma are eligible if they have MRI-defined clinical stage II or III disease according to AJCC 8th edition, tumor located within 12 cm from the anal verge, and at least one high-risk feature, including cT4b, cN2, EMVI". Sites: China. No results are recorded here; the registry entry is the source.